title: Comparative antiplaque activity of sanguinarine and chlorhexidine in man.
abstract: This clinical investigation examined the effect of a sanguinarine extract on bacterial plaque growth in man. Three different mouthrinses were examined: (i) Veadent containing 0.03% sanguinarine and 0.2% zinc chloride (test rinse); (ii) a vehicle solution containing all the excipients of Veadent except the 0.03% sanguinarine (control rinse); (iii) Hibident a 0.2% chlorhexidine digluconate formulation (positive control rinse). The trial in which 12 dental students participated, was designed as a single-blind, cross-over study. During 3 experimental periods of 18 days, the participants refrained from mechanical oral hygiene and rinsed twice a day with one of the above mentioned solutions. Between experimental phases, a wash-out period of 11 days was instituted. In each subject, 4 teeth were randomly selected for assessment. Clinical evaluations were performed at days 1 (0, 4, 8, 12 hours), 2, 4, 11 and 18. The plaque on the buccal surfaces of the selected teeth was disclosed with neutral red 0.05% and colour slides taken. The % of the tooth surface covered with plaque was calculated planimetrically from these colour slides. The present results show an excellent anti-plaque effect with Hibident, a very small effect with Veadent and a negligible effect with the vehicle solution without the sanguinarine. These findings would suggest that the Veadent mouthrinse would have at most only a limited role as a plaque inhibitor.
authors.affiliation: Department of Periodontology, School of Dentistry, Faculty of Medicine, Catholic University of Leuven, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Quirynen
authors.forename: M
authors.initials: M
authors.lastname: Marechal
authors.forename: D
authors.initials: D
authors.lastname: van Steenberghe
mesh_terms: D000328:Adult; D000470:Alkaloids / Q000008:administration & dosage / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053119:Benzophenanthridines; D002710:Chlorhexidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002712:Chlorides / Q000627:therapeutic use; D003773:Dental Plaque / Q000517:prevention & control*; D003774:Dental Plaque Index; D006801:Humans; D007546:Isoquinolines; D009067:Mouthwashes; D016037:Single-Blind Method; D013997:Time Factors; D015032:Zinc / Q000627:therapeutic use; D017967:Zinc Compounds
chemical_list: D000470:Alkaloids; D000890:Anti-Infective Agents; D053119:Benzophenanthridines; D002712:Chlorides; D007546:Isoquinolines; D009067:Mouthwashes; D017967:Zinc Compounds; C016837:zinc chloride; C005705:sanguinarine; D015032:Zinc; C010882:chlorhexidine gluconate; D002710:Chlorhexidine